Atossa Genetics (ATOS) Announces IRB Approval of Oral Endoxifen as Post-Mastectomy Treatment for U.S. Breast Cancer Patient

March 26, 2019 8:34 AM EDT Send to a Friend
Atossa Genetics Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods to treat breast cancer and ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to Premium below (Free Trial) LEARN MORE

Member Login